Aspire Biopharma Holdings, Inc. (ASBP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aspire Biopharma Holdings, Inc., a Delaware corporation and emerging growth company, on May 14, 2026, covering events occurring on May 11, 2026. The Company is headquartered in Estero, Florida, and its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols "ASBP" and "ASBPW," respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance action and does not contain financial performance data.
Material Changes
The primary material change reported is the filing of a Certificate of Amendment to the Company's Certificate of Incorporation with the Delaware Secretary of State on May 11, 2026. This amendment effects a 1-for-30 reverse stock split of the Company's issued and outstanding common stock. Key details of the change include:
- Split Ratio: Every 30 shares of pre-split common stock will be combined into 1 share.
- Fractional Shares: No fractional shares will be issued; any resulting fractions will be rounded up to the nearest whole share.
- Trading Symbol: The symbol will remain "ASBP."
- CUSIP: The new CUSIP number following the split is 738920305.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or an outlook for future periods. No specific risks or contingencies related to the reverse split are detailed in the text, other than the standard rounding of fractional shares. The Company has elected to use the extended transition period for complying with new or revised financial accounting standards as an emerging growth company.
Investor Verification Checklist
- Verify the exact effective time of the 1-for-30 reverse stock split as set forth in the Certificate of Amendment (Exhibit 3.1).
- Confirm the treatment of fractional shares for specific shareholder holdings (rounded up to the nearest whole share).
- Check the updated CUSIP number (738920305) for trading and settlement purposes.
- Review the full text of the Certificate of Amendment filed as Exhibit 3.1 for any additional terms not summarized here.